BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 14574516)

  • 21. 2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation.
    Jungehülsing M; Scheidhauer K; Damm M; Pietrzyk U; Eckel H; Schicha H; Stennert E
    Otolaryngol Head Neck Surg; 2000 Sep; 123(3):294-301. PubMed ID: 10964310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of clinical utility of 18F-FDG PET in patients with head and neck cancer: a probability analysis.
    Goerres GW; Mosna-Firlejczyk K; Steurer J; von Schulthess GK; Bachmann LM
    Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):562-71. PubMed ID: 12589477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.
    McCollum AD; Burrell SC; Haddad RI; Norris CM; Tishler RB; Case MA; Posner MR; Van den Abbeele AD
    Head Neck; 2004 Oct; 26(10):890-6. PubMed ID: 15390197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.
    Yao M; Smith RB; Graham MM; Hoffman HT; Tan H; Funk GF; Graham SM; Chang K; Dornfeld KJ; Menda Y; Buatti JM
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):991-9. PubMed ID: 16099601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose.
    Greven KM; Keyes JW; Williams DW; McGuirt WF; Joyce WT
    Cancer; 1999 Jul; 86(1):114-8. PubMed ID: 10391570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymph node metastasis of squamous cell carcinoma from an unknown primary: impact of positron emission tomography.
    Stoeckli SJ; Mosna-Firlejczyk K; Goerres GW
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):411-6. PubMed ID: 12634970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of PET FDG in the management of head and neck squamous cell cancer.
    Wong WL; Saunders M
    Clin Oncol (R Coll Radiol); 1998; 10(6):361-6. PubMed ID: 9890536
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer.
    Higashi K; Nishikawa T; Seki H; Oguchi M; Nambu Y; Ueda Y; Yuasa K; Tonami H; Okimura T; Yamamoto I
    J Nucl Med; 1998 Jan; 39(1):9-15. PubMed ID: 9443730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of thallium-201 and F-18 FDG SPECT uptake in squamous cell carcinoma of the head and neck.
    Mukherji SK; Drane WE; Tart RP; Landau S; Mancuso AA
    AJNR Am J Neuroradiol; 1994 Nov; 15(10):1837-42. PubMed ID: 7863932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma.
    Murakami R; Uozumi H; Hirai T; Nishimura R; Shiraishi S; Ota K; Murakami D; Tomiguchi S; Oya N; Katsuragawa S; Yamashita Y
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):377-82. PubMed ID: 17321066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myocardial distribution of (18)F-FDG and (99m)Tc-sestamibi on dual-isotope simultaneous acquisition SPET compared with PET.
    Matsunari I; Kanayama S; Yoneyama T; Matsudaira M; Nakajima K; Taki J; Nekolla SG; Takekoshi N; Tonami N; Hisada K
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1357-64. PubMed ID: 12271419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of FDG-PET/CT on the management of head and neck tumours: the radiotherapist's perspective.
    Dietl B; Marienhagen J; Kühnel T; Schreyer A; Kölbl O
    Oral Oncol; 2008 May; 44(5):504-8. PubMed ID: 17826307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors.
    AAssar OS; Fischbein NJ; Caputo GR; Kaplan MJ; Price DC; Singer MI; Dillon WP; Hawkins RA
    Radiology; 1999 Jan; 210(1):177-81. PubMed ID: 9885604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does 18fluoro-fluorodeoxyglucose positron emission tomography improve recurrence detection in patients treated for head and neck squamous cell carcinoma with negative clinical follow-up?
    Salaun PY; Abgral R; Querellou S; Couturier O; Valette G; Bizais Y; Kraeber-Bodéré F
    Head Neck; 2007 Dec; 29(12):1115-20. PubMed ID: 17636537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma.
    Schwartz DL; Ford E; Rajendran J; Yueh B; Coltrera MD; Virgin J; Anzai Y; Haynor D; Lewellyn B; Mattes D; Meyer J; Phillips M; Leblanc M; Kinahan P; Krohn K; Eary J; Laramore GE
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):129-36. PubMed ID: 15629603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Technetium-99m-MIBI in primary and recurrent head and neck tumors: contribution of bone SPECT image fusion.
    Leitha T; Glaser C; Pruckmayer M; Rasse M; Millesi W; Lang S; Nasel C; Backfrieder W; Kainberger F
    J Nucl Med; 1998 Jul; 39(7):1166-71. PubMed ID: 9669388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positron emission imaging of head and neck cancer, including thyroid carcinoma.
    Schöder H; Yeung HW
    Semin Nucl Med; 2004 Jul; 34(3):180-97. PubMed ID: 15202100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report.
    Yao M; Graham MM; Smith RB; Dornfeld KJ; Skwarchuk M; Hoffman HT; Funk GF; Graham SM; Menda Y; Buatti JM
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1410-8. PubMed ID: 15590172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.